Abstract 128P
Background
Biliary tract cancers are heterogeneous tumors defined by the anatomical location, intrahepatic, cholangiocarcinoma (ICC), extrahepatic (ECC), gallbladder and ampulla of Vater cancer (AVC).The outcome of treatment by location remains unclear in Latin American population, resulting in inconsistently data to enhance treatment decisions and outcome. The aim of this study is to describe the epidemiological features and prognosis of overall survival of Latin American population with biliary tract cancers.
Methods
Retrospective, observational study. Included patients treated at the National Cancer Institute between 2008 and 2022. Statistical analysis required: X2 and t test, Kaplan Meier, Log Rank and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.
Results
A total 786 of patients diagnosed with biliary tract cancer were included in the analysis. Patients had a median age of 61 years (24-96). Alcohol consumption and smoking were observed in 22% and 29% respectively. Regarding comorbidities, 22% had Type2DM, 27% HAS, and obesity & overweight was present in 13% and 32% respectively. Anatomical location included ICC (19%;n=151), ECC (22%;n=172), gallbladder (33%;n=259) and AVC (26%;n=204). Female were more prevalent in gallbladder and ICC (79% & 71%) (p<0.001). Median time to diagnosis was 3 months (0–120); extent of disease was observed as localized (18%;n=144), local-advanced (20%;n=158), and metastatic (60%;n=472). In metastatic patients, mean number of metastasis was 1 (1-7), being liver (66%), retroperitoneum (7%), and lung (6%) the most frequent sites. Comparing Chemotherapy and extent of disesase, 35%, 53%, and 55% patients received treatment for localized, unresectable, and metastatic (p=0.001). An OS analysis was conducted considering location, ICC patients showed a median-OS of 9months, ECC a median-OS of 12months, gallbladder a median-OS of 1months and AVC did not reach median-OS (p<0.001).
Conclusions
Prognosis and outcome for patients with biliary tract cancer differ depending on the anatomical subsite. This is one of the main studies describing epidemiological features, and outcome in Latin American patients with biliary tract.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17